Your session is about to expire
← Back to Search
Pembrolizumab + Chemotherapy for Hodgkin's Lymphoma (KEYNOTE-C11 Trial)
KEYNOTE-C11 Trial Summary
This trial will test whether pembrolizumab, a cancer immunotherapy drug, is more effective than chemotherapy at treating non-small cell lung cancer.
KEYNOTE-C11 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowKEYNOTE-C11 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183KEYNOTE-C11 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer has spread to my brain or spinal cord.I have been treated for an autoimmune disease in the last 2 years.I have been treated with drugs targeting immune checkpoints.I am fully active or restricted in physically strenuous activity but can do light work.I have been diagnosed with nodular lymphocyte-predominant Hodgkin Lymphoma.I have an immune system disorder or have been on steroids or other immune-weakening medicines in the last week.I have not had a live vaccine within 30 days before starting the study treatment.I have a heart condition that is not well-managed.I have or had pulmonary fibrosis.My Hodgkin Lymphoma is at an advanced stage or has high-risk factors.I have received an organ or tissue transplant from another person.I have another cancer that is getting worse or was treated in the last 5 years.I have or had lung inflammation that needed steroids.I haven't had any treatment for classical Hodgkin lymphoma before this study.
- Group 1: Pembrolizumab Monotherapy + Chemotherapy + Pembrolizumab Consolidation
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is Pembrolizumab a safe and effective treatment for individuals?
"Given that Pembrolizumab is currently in Phase 2, the safety of this drug was estimated as a 2 on Power's scale. This implies that there are some results indicating safety but no evidence for efficacy yet."
How many healthcare facilities are participating in the research of this trial?
"Currently, 11 medical centres are enrolling participants for this clinical trial. These locations include Las Vegas, Fullerton and Edmonton in addition to 8 other cities. It is recommended that those interested select the nearest site available so as to reduce travel obligations."
Are there any vacancies in the research protocol that participants can join?
"The records available on clinicaltrials.gov suggest that this trial is now closed for recruitment, having first been posted on October 7th 2021 and last updated July 12th 2022. Nevertheless, there are still 3970 other trials recruiting patients at the moment."
Is this trial a pioneering effort in its field?
"To date, 2246 studies with Pembrolizumab have been conducted in 79 countries and 3969 cities. The inaugural trial of this medication occurred back in 1997, sponsored by Alfacell; it enrolled 300 participants and achieved Phase 3 approval status. Since then, 2389 trials involving the drug have concluded."
How is Pembrolizumab typically employed in medical treatments?
"As a common treatment for advanced testicular cancer, pembrolizumab has also been used to alleviate symptoms of conditions such as ulcerative colitis and varicella-zoster virus acute retinal necrosis. Additionally, the drug can be utilized in treating pheochromocytomas."
Are there precedents of Pembrolizumab being used in medical research?
"Pembrolizumab was initially explored in 1997 at Butterworth Campus of Spectrum Health Hospital. Now, 2389 trials have been concluded and 2246 are actively being conducted - with a significant number occurring in Las Vegas, Nevada."
How many participants are enrolled in this clinical experiment?
"Unfortunately, no new patients are being accepted for this trial at the present moment. The study was first published on October 7th 2021 and has been edited most recently on July 12th 2022. In case you're searching for other research endeavours, there currently exist 1724 studies actively looking for participants with Hodgkin Disease along with 2246 studies in search of Pembrolizumab candidates."
Share this study with friends
Copy Link
Messenger